- Home
- TNGX vs CTLP Comparison
TNGX vs CTLP Comparison
Compare TNGX & CTLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CTLP
- Stock Information
- Founded
- TNGX 2014
- CTLP 1992
- Country
- TNGX United States
- CTLP United States
- Employees
- TNGX N/A
- CTLP N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CTLP EDP Services
- Sector
- TNGX Health Care
- CTLP Technology
- Exchange
- TNGX Nasdaq
- CTLP Nasdaq
- Market Cap
- TNGX 723.2M
- CTLP 797.4M
- IPO Year
- TNGX N/A
- CTLP N/A
- Fundamental
- Price
- TNGX $7.58
- CTLP $10.60
- Analyst Decision
- TNGX Strong Buy
- CTLP Hold
- Analyst Count
- TNGX 6
- CTLP 4
- Target Price
- TNGX $10.00
- CTLP $12.00
- AVG Volume (30 Days)
- TNGX 2.6M
- CTLP 2.0M
- Earning Date
- TNGX 11-05-2025
- CTLP 11-06-2025
- Dividend Yield
- TNGX N/A
- CTLP N/A
- EPS Growth
- TNGX N/A
- CTLP 473.33
- EPS
- TNGX N/A
- CTLP 0.86
- Revenue
- TNGX $24,296,000.00
- CTLP $302,548,000.00
- Revenue This Year
- TNGX $20.42
- CTLP $18.25
- Revenue Next Year
- TNGX N/A
- CTLP $12.30
- P/E Ratio
- TNGX N/A
- CTLP $12.33
- Revenue Growth
- TNGX N/A
- CTLP 12.64
- 52 Week Low
- TNGX $1.03
- CTLP $7.01
- 52 Week High
- TNGX $8.80
- CTLP $11.36
- Technical
- Relative Strength Index (RSI)
- TNGX 51.87
- CTLP 39.16
- Support Level
- TNGX $7.66
- CTLP $10.55
- Resistance Level
- TNGX $8.80
- CTLP $10.61
- Average True Range (ATR)
- TNGX 0.51
- CTLP 0.06
- MACD
- TNGX -0.04
- CTLP 0.00
- Stochastic Oscillator
- TNGX 33.70
- CTLP 17.50
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.